WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera's SQore™ platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass.
Yuhong Zeng, Ph.D., Director of Formulation at Comera, will present data from Comera's SQore platform which is designed to transform intravenous biologics such as monoclonal antibodies (mAbs) into subcutaneous (SQ) formulations. Comera's SQore platform has been successfully tested with over 40 mAbs, with viscosity reductions of up to 85%. Comera uses the SQore platform to identify the driving forces for high viscosity and select excipients that inhibit attractive protein-protein interactions to lower viscosity.
Robert Mahoney, Ph.D., Chief Scientific Officer at Comera, commented, "The challenge many have faced with SQ delivery is that high-concentration antibody solutions can become viscous, and prone to physical instability, such as aggregation, precipitation, or denaturation. We have been able to successfully reduce the viscosity of a diverse range of monoclonal antibodies, demonstrating the versatility and remarkable capabilities of our SQore platform."
Comera is also presenting data from a preclinical study, previously published in the Journal of Pharmaceutical Sciences, that found that a caffeine excipient reduced viscosity of the monoclonal antibody ipilimumab without any adverse impact on antibody pharmacokinetic properties. The addition of one or more excipients, such as caffeine, selectively interrupts intermolecular interactions to reduce viscosity of high concentration mAb formulations.
Dr. Mahoney continued, "The data reinforces the strength of our SQore platform in reformulating high-viscosity monoclonal antibody solutions and underscores the potential ...